secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001854270-23-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports FY2022 net loss of $58.2M; cash runway through Q1 2024; IND on track for H2 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents & short-term investments of $98.6M as of Dec 31, 2022; expect funding through at least Q1 2024.
- FY2022 net loss $58.2M ($2.23 per share) vs $55.3M ($19.00 per share) in 2021; R&D expenses $34.1M, G&A $40.8M.
- SENTI-202 IND application for AML/MDS planned in H2 2023; preclinical data to be presented at AACR April 2023.
- Capital expenditures of $8.5M in Q4 2022 driven by cGMP manufacturing facility buildout and equipment.
- Collaborations with Spark Therapeutics and BlueRock Therapeutics advancing Gene Circuit programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/0001854270-23-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/snti-20230322.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer